The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis

Mead Johnson Nutrition

Status: Withdrawn

Conditions: Atopic Dermatitis

Treatments: Dietary Supplement: High Olive Oil; Dietary Supplement: DHA+EPA; Dietary Supplement: DHA

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01936194

6018

Details and patient eligibility

About

This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants at increased risk.

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Woman is pregnant between 16 and 20 weeks
• Mother delivers after 36 weeks
• Mother is willing to breast-feed for four months
• Mother has potential to deliver a child with increased risk of atopic dermatitis
• Signed Informed Consent

Exclusion criteria

• Mother is smoking
• Disease with influence on breast feeding
• Complicated pregnancy
• Allergic to seafood
• Allergic to soy
• Allergic to marine fish
• Mother has more than two salmon or tuna meals per week
• Mother is undergoing treatment with anticoagulants

Trial design

0 participants in 3 patient groups

Docosahexaenoic Acid (DHA)

Experimental group

Description:

infants receiving capsule containing DHA.

Treatment:

Dietary Supplement: DHA

High Olive Oil

Other group

Description:

infants receiving capsule without DHA and EPA.

Treatment:

Dietary Supplement: High Olive Oil

DHA+EPA

Experimental group

Description:

infants receiving capsule containing DHA and EPA.

Treatment:

Dietary Supplement: DHA+EPA